Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'

Leuk Lymphoma. 2019 Dec;60(14):3565-3568. doi: 10.1080/10428194.2019.1636989. Epub 2019 Jul 9.
No abstract available

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Dexamethasone / administration & dosage
  • Drug Resistance, Neoplasm / drug effects*
  • Female
  • Follow-Up Studies
  • Humans
  • Italy
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / pathology
  • Prognosis
  • Retrospective Studies
  • Salvage Therapy*
  • Survival Rate
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives

Substances

  • Thalidomide
  • Dexamethasone
  • pomalidomide